# H2AC20

## Overview
H2AC20 is a gene that encodes the H2A clustered histone 20 protein, a variant of the histone H2A family. This protein is integral to the structure of chromatin, playing a crucial role in the regulation of gene expression by modulating nucleosome dynamics and DNA accessibility. As a histone variant, H2A clustered histone 20 is involved in the regulation of oncogenes and cancer cell behavior, particularly in breast cancer, where it influences EGF signaling pathways. The gene's expression is notably stimulated by epidermal growth factor (EGF), contributing to a feedback loop that enhances cell proliferation and epithelial-mesenchymal transition (EMT) (Espiritu2021Molecular). Additionally, H2AC20 has been identified as a differentially expressed gene in pancreatic adenocarcinoma, suggesting its potential as a biomarker for this type of cancer (Jafari2022Identification). Despite its recognized roles in cancer biology, further research is necessary to fully understand the specific interactions and mechanisms of H2AC20 in various cancer contexts.

## Clinical Significance
The H2AC20 gene, also known as HIST2H2AC, plays a significant role in cancer, particularly breast cancer. Alterations in the expression of H2AC20 have been linked to the regulation of EGF signaling, which is crucial for cell proliferation, growth, and epithelial-mesenchymal transition (EMT) in breast cancer. The gene's expression is stimulated by EGF, creating a positive feedback loop that promotes cancer progression (Espiritu2021Molecular). In breast cancer, HIST1H2AC, a related histone variant, is upregulated in ER-positive tissues and cell lines, correlating with poor prognosis. It enhances the expression of estrogen receptor target genes by recruiting the ERα transcription factor, and its depletion impairs estrogen signaling and reduces cell proliferation. Patients with low HIST1H2AC expression respond better to anthracycline chemotherapy, while high expression is associated with resistance (Dhahri2024Beyond).

In pancreatic cancer, H2AC20 has been identified as a differentially expressed gene, suggesting its potential role as a biomarker for the disease. However, specific details about its clinical significance in pancreatic cancer remain unclear (Jafari2022Screening). Additionally, H2AC20 was noted among differentially expressed genes in a study comparing BRCA1 hypermethylated and BRCA1-null triple-negative breast cancers, though its specific clinical implications were not detailed (Glodzik2020Comprehensive).

## Interactions
H2AC20, a variant of the histone H2A protein, plays a significant role in the regulation of oncogenes and cancer cell behavior, particularly in breast cancer. It is a major regulator of EGF signaling, where its expression is stimulated by EGF, creating a positive feedback loop that enhances EGF-induced cell proliferation, growth, and epithelial-mesenchymal transition (EMT) (Espiritu2021Molecular). This interaction suggests that H2AC20 is involved in the modulation of nucleosome dynamics, impacting DNA accessibility and transcription factor binding, which are crucial processes in cancer progression and treatment (Espiritu2021Molecular).

In the context of pancreatic adenocarcinoma, H2AC20 is identified as one of the differentially expressed genes, being downregulated in cancerous tissues compared to normal tissues. This downregulation indicates its potential role as a biomarker for pancreatic cancer, although specific protein interactions involving H2AC20 in this context are not detailed (Jafari2022Identification). The involvement of H2AC20 in these processes highlights its importance in cancer biology, although further research is needed to elucidate its specific interactions and mechanisms.


## References


[1. (Glodzik2020Comprehensive) Dominik Glodzik, Ana Bosch, Johan Hartman, Mattias Aine, Johan Vallon-Christersson, Christel Reuterswärd, Anna Karlsson, Shamik Mitra, Emma Niméus, Karolina Holm, Jari Häkkinen, Cecilia Hegardt, Lao H. Saal, Christer Larsson, Martin Malmberg, Lisa Rydén, Anna Ehinger, Niklas Loman, Anders Kvist, Hans Ehrencrona, Serena Nik-Zainal, Åke Borg, and Johan Staaf. Comprehensive molecular comparison of brca1 hypermethylated and brca1 mutated triple negative breast cancers. Nature Communications, July 2020. URL: http://dx.doi.org/10.1038/s41467-020-17537-2, doi:10.1038/s41467-020-17537-2. This article has 57 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-020-17537-2)

2. (Jafari2022Screening) Screening and identification of potential biomarkers for pancreatic cancer: An integrated bioinformatics analysis. This article has 0 citations.

[3. (Dhahri2024Beyond) Hejer Dhahri, Wesley N. Saintilnord, Darrell Chandler, and Yvonne N. Fondufe-Mittendorf. Beyond the usual suspects: examining the role of understudied histone variants in breast cancer. International Journal of Molecular Sciences, 25(12):6788, June 2024. URL: http://dx.doi.org/10.3390/ijms25126788, doi:10.3390/ijms25126788. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms25126788)

4. (Jafari2022Identification) Identification of new biomarkers for pancreatic cancer management: A bioinformatics analysis. This article has 1 citations.

[5. (Espiritu2021Molecular) Daniel Espiritu, Anna K. Gribkova, Shubhangi Gupta, Alexey K. Shaytan, and Anna R. Panchenko. Molecular mechanisms of oncogenesis through the lens of nucleosomes and histones. The Journal of Physical Chemistry B, 125(16):3963–3976, March 2021. URL: http://dx.doi.org/10.1021/acs.jpcb.1c00694, doi:10.1021/acs.jpcb.1c00694. This article has 19 citations.](https://doi.org/10.1021/acs.jpcb.1c00694)